Advanced search
Publication Cover
Acta Cardiologica Volume 65, 2010 - Issue 1
Submit an article Journal homepage
7
Views
0
CrossRef citations to date
0
Altmetric
Articles

Catastrophic rapid onset heparin-induced thrombocytopenia - Victim of our own success

Sudip NandaDept. of Internal Medicine, St.Luke’s Hospital, Bethlehem, Pennsylvania, U.S.A.Correspondence[email protected]
, MD,
Shree Gopal SharmaDepartment of Pathology, University of Arkansas, Arkansas, U.S.A.
, MD &
Santo LongoDepartment of Pathology, St.Luke’s Hospital, Bethlehem, Pennsylvania, U.S.A.
, MD
Pages 93-95 | Received 10 Oct 2008, Accepted 27 Oct 2009, Published online: 23 May 2017

References

  • Hochman JS, Wali AU, Gavrila D, Sim MJ, Malhotra S. Palazzo AM, De La Fuente B. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999; 138: 313–8.
  • Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127: 35S-45S.
  • Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286–92.
  • Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002; 126: 1415–23.
  • Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001; 113: 886–90.
  • Council for International Organization of Medical Sciences (CIOMS). Benefit-risk balance for marketed drugs: evalu-ating safety signals The report of CIOMS Working Party IV, Geneva, Switzerland, 1998.
  • Warkentin TE, Greinacher A. Treatment and prevention of heparin-induced thrombocytopenia. ACCP Evidence-Based Clinical Practice Guidelines, 8th edition. Chest 2008; 133: Supplement 3405–3805.
  • Refaai MA, Van Cott EM, Laposata M. The timing of a positive test result for heparin-induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases. Am J Clin Pathol 2003; 119: 497–504.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.